Cargando…

Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: a case report

The use of immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in the treatment of various malignancies, significantly reshaping cancer treatment. However, as a result of the widespread use of ICIs, several immune-related adverse events (iRAEs) have emerged, some of which can be rare a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Guo, Zhao, Haina, Yin, Yuxuan, Shen, Hailin, Zeng, Zhaohao, Yang, Jianwei, Zhang, Lili
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619899/ https://www.ncbi.nlm.nih.gov/pubmed/37920461 http://dx.doi.org/10.3389/fimmu.2023.1253463

Ejemplares similares

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Radiation Recall Pneumonitis Induced by Sintilimab: A Case Report and Literature Review
por: Wang, Min, et al.
Publicado: (2022)

Pre-immunotherapy radiotherapy enhanced the efficacy of multi-line sintilimab in unresectable advanced esophageal squamous cell carcinoma
por: Xu, Shuhui, et al.
Publicado: (2023)

Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress
por: Ji, Hongxiang, et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression
por: Wen, Liang, et al.
Publicado: (2020)

Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study
por: Liu, Chengxin, et al.
Publicado: (2023)

Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies
por: Shi, Jia, et al.
Publicado: (2021)

Upper Gastrointestinal Tract IrAEs: A Case Report About Sintilimab-Induced Acute Erosive Hemorrhagic Gastritis
por: Ai, Qi, et al.
Publicado: (2022)

Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report
por: Li, Haoqian, et al.
Publicado: (2023)

Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies
por: Farini, Andrea, et al.
Publicado: (2021)

Predictors of cardiac involvement in idiopathic inflammatory myopathies
por: Bandeira, Matilde, et al.
Publicado: (2023)

Idiopathic inflammatory myopathy and non-coding RNA
por: Yang, Yang, et al.
Publicado: (2023)

Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
por: Tu, Lingfang, et al.
Publicado: (2021)

Case report: Advanced primary squamous cell carcinoma in the periampullary area with upregulation of programmed cell death-ligand 1 expression and response to sintilimab immunotherapy
por: Wang, Baoshan, et al.
Publicado: (2023)

Sintilimab: Pneumonitis: case report
Publicado: (2021)

Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
por: Li, Gang, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)

A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy
por: Reed, Ann Marie, et al.
Publicado: (2019)

Deciphering the crosstalk of immune dysregulation between COVID-19 and idiopathic inflammatory myopathy
por: Zhang, Zhao, et al.
Publicado: (2023)

The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Zhao, Zheng, et al.
Publicado: (2023)

Inflammatory myopathies and beyond: The dual role of neutrophils in muscle damage and regeneration
por: Torres-Ruiz, Jiram, et al.
Publicado: (2023)

Serum metabolomic analysis reveals disorder of steroid hormone biosynthesis in patients with idiopathic inflammatory myopathy
por: Huo, Tong, et al.
Publicado: (2023)

Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis
por: Li, Shuling, et al.
Publicado: (2022)

High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies
por: Wilfong, Erin M., et al.
Publicado: (2022)

Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis
por: Zhen, Chao, et al.
Publicado: (2022)

Sintilimab-induced autoimmune diabetes: A case report and review of the literature
por: Yang, Jing, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Diagnostic value and mechanism of plasma S100A1 protein in acute ischemic stroke: a prospective and observational study
por: Hong, Guo, et al.
Publicado: (2023)

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy
por: Jia, Lin, et al.
Publicado: (2022)

Sintilimab-Induced Myocarditis in a Patient with Gastric Cancer: A Case Report and Literature Review
por: Liu, Xin, et al.
Publicado: (2023)

Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
por: Liu, Lulu, et al.
Publicado: (2023)

Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?
por: Corona-Sanchez, Esther Guadalupe, et al.
Publicado: (2022)

Muscle fiber necroptosis in pathophysiology of idiopathic inflammatory myopathies and its potential as target of novel treatment strategy
por: Kamiya, Mari, et al.
Publicado: (2023)

Sintilimab: Aggravation of Coronavirus disease 2019: case report
Publicado: (2021)

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma
por: You, Maojin, et al.
Publicado: (2022)

A rare presentation of Sintilimab-induced swelling along the vessels: Case report
por: Liu, Liqiong, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
por: Li, Dailong, et al.
Publicado: (2022)

Autoimmune Myopathies: Where Do We Stand?
por: Simon, Jean-Philippe, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bn5himghqdv8uugjehgli2v56j